BD deepens localization R&D and production layout medical whole industry chain

On June 17, BD, a medical technology company, announced that its Greater China R&D Center was officially opened and opened. At the same time, the BD pharmaceutical system pre-filled syringe production line was launched. This move marks BD's establishment of a complete industrial chain covering R&D, production, marketing and sales in China. It has once again achieved milestones and will bring faster, more efficient and more effective Chinese medical staff, researchers and patients. A solution that meets local needs and continues to deepen the localization strategy of BD “rooting China and serving China”.

Deng Jianmin, senior vice president of BD Global/General Manager of Greater China, said: “BD has been in China for more than 20 years in 1994. Establishing high-quality localized multinational companies in China has been a constant pursuit of BD. Entering China In the second year, BD has begun to build the first factory in China; today, in the context of China's new economy, BD is still full of confidence in the Chinese market, and continues to increase investment in China, today's R&D center and The dual investment in the production line is the most powerful proof of BD's commitment to China."

Yang Zhiju, director of the Suzhou Industrial Park Management Committee, said: “The Suzhou Industrial Park has been committed to providing the best development environment for the park enterprises for more than 20 years. We are very happy to see the entire industrial chain of BD in China from production to R&D. Continuously extending, it will continue to provide quality services to park enterprises including BD, support the sustainable development of park enterprises, and further implement the implementation and promotion of the national 'Health China' strategy."

Layout research and development dual center, local research and development and upgrade

Through the establishment of a new Greater China R&D Center, BD China has formed a “Development and Development Center” with Shanghai as the innovation design center and Suzhou as the experimental center. Among them, the Shanghai R&D Center will focus on discovering the actual pain points and needs of local medical staff and patients, and carry out related solution design; Suzhou R&D Center will build a series of world-class laboratories, research and development of experimental work, and research results to actual production. Conversions, etc. are all expanded here.

Liquid Injection

Tetanus Shot,Tetanus Vaccine,Hepatitis B Injection,Hep B Vaccine

FOSHAN PHARMA CO., LTD. , https://www.fs-pharma.com